When did TransMedics Group, Inc. report Q4 2024 earnings?

TransMedics Group, Inc. (TMDX) reported Q4 2024 earnings on February 27, 2025 after market close.

What were TransMedics Group, Inc.'s Q4 2024 revenue and EPS?

TransMedics Group, Inc. reported revenue of $121.6M and eps of $0.19 for Q4 2024.

Did TransMedics Group, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $109.5M by $12.1M. EPS missed the consensus estimate of $0.22 by $0.03.

Where can I find TransMedics Group, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-029104) directly on SEC EDGAR. The filing index links above go to sec.gov.

TransMedics Group, Inc. TMDX Q4 2024 Annual earnings

Reported February 27, 2025 · After market close

Revenue$121.6MBeat by $12.1M

EPS$0.19Miss by $0.03

Revenue estimate$109.5M

EPS estimate$0.22

Next report

Aug 4, 2026 (In 5 days)

Revenue estimate$183.8M

EPS estimate$0.50

Financials

Q4 2024

Income statement

See full

Revenue$121.6M+49.8%

Gross profit$72.0M+50.3%

Operating income$8.6M—

Net income$6.9M—

EPS (diluted)$0.20—

Balance sheet

See full

Cash & equivalents$336.7M-14.7%

Total debt$68.3M-0.7%

Total equity$228.6M+66.6%

Total assets$804.1M+13.9%

Cash flow

See full

Operating cash flow$19.7M—

CapEx$13.6M-67.5%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$2.09B-18.8%

Enterprise value$1.82B-18.9%

P/E59×—

P/S4.7×-5.9×

Profitability

See full

Gross margin59.4%-4.4pp

Operating margin8.5%+5.3pp

Net margin8%—

Returns & leverage

See full

Return on equity19.4%—

Debt / equity0.3×-0.2×

Current ratio8.3×-1.0×

Segments

By product

See full

Liver Product$89.0M+62.6%

Heart Product$28.1M+35.2%

Lung Product$3.4M+6.8%

By segment

See full

Ocs Transplant Revenue$120.5M+53.1%

Versus estimates

Revenue

Q1 2026$173.9MMiss by $503.3K Q4 2025$160.8MBeat by $5.4M Q3 2025$143.8MMiss by $11.6M Q2 2025$157.4MBeat by $15.7M Q1 2025$143.5MBeat by $20.1M

Q4 2024$121.6MBeat by $12.1M

Diluted EPS

Q1 2026$0.30Miss by $0.32 Q4 2025$0.57Beat by $0.16 Q3 2025$0.66Beat by $0.29 Q2 2025$0.92Beat by $0.44 Q1 2025$0.70Beat by $0.41

Q4 2024$0.19Miss by $0.03

Ask the moment TransMedics Group, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did TransMedics Group, Inc. report Q4 2024 earnings?: TransMedics Group, Inc. (TMDX) reported Q4 2024 earnings on February 27, 2025 after market close.
What were TransMedics Group, Inc.'s Q4 2024 revenue and EPS?: TransMedics Group, Inc. reported revenue of $121.6M and eps of $0.19 for Q4 2024.
Did TransMedics Group, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $109.5M by $12.1M. EPS missed the consensus estimate of $0.22 by $0.03.
Where can I find TransMedics Group, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-029104) directly on SEC EDGAR. The filing index links above go to sec.gov.